Abstract
Background: The human brain natriuretic peptide (hBNP), a cardioprotective hormone released from the heart by cardiomyocytes stretching and neurohormonal activation, emerged as a new biomarker in the diagnosis of congestive heart failure, myocardial ischemia or acute coronary syndrome. BNP in the plasma strikingly increases in left ventricular dysfunction from several causes. Objective: To evaluate hBNP assays in diagnostic, prognostic and guiding treatment strategies in heart failure and other cardiovascular diseases, and to assess the clinical use of recombinant hBNP. Methods: Analysis of hBNP and NT-proBNP as suitable markers for clinical use and application of hBNP in management of acute decompensated heart failure. Results/conclusion: hBNP assays provide useful information for the diagnosis of various heart pathologies, particularly when used with other clinical tests such as echocardiography. They also provide prognostic values for future cardiovascular events. However, use of recombinant BNP for managing acute decompensated heart failure should be limited because it has been associated with both renal dysfunction and increased risk of mortality.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
